NeXT Personal Dx - Personalis Powered to see MRD that previously avoided detection 1-6 NeXT Personal® Dx is a tumor-informed molecular residual disease (MRD) liquid biopsy with ultra-high sensitivity and sp
Careers in Precision Oncology - Personalis We’re looking for team members who are driven to advance the field of precision oncology Together, we can transform the future of cancer care
Personalis Announces Publication Validating NeXT Personal® Test for . . . In the analytical validation study published in Oncotarget, scientists from Personalis evaluated NeXT Personal by testing samples from over 120 patients across nine cancer types and paired tumor and normal cell lines The NeXT Personal technology leverages whole genome sequencing (WGS) and advanced noise suppression with NeXT SENSE